JAMA Network
About The Study: Zerlasiran, a small-interfering RNA targeting hepatic synthesis of apolipoprotein(a), was well-tolerated and reduced time-averaged lipoprotein(a) concentration by more than 80% during 36 weeks of treatment in patients with atherosclerotic cardiovascular disease.
Corresponding Author: To contact the corresponding author, Steven E. Nissen, MD, email [email protected].
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.21957)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
